BACKGROUND: The association of COVID-19 with higher bleeding risk and worse outcomes in acute ischemic stroke (AIS) undergoing revascularization may be related to the presence of infection symptoms. We aimed to assess the safety and outcomes of revascularization treatments in patients with AIS with asymptomatic COVID-19 (AS-COVID) or symptomatic COVID-19 (S-COVID). METHODS: We conducted an international multicenter retrospective cohort study of consecutive AIS tested for SARS-CoV-2, receiving intravenous thrombolysis and endovascular treatment between 2020 and 2021. We compared COVID-negative controls, AS-COVID, and S-COVID using multivariable regression. We assessed symptomatic intracranial hemorrhage (symptomatic intracerebral hemorrhage), mortality, and 3-month disability (modified Rankin Scale score). RESULTS: Among 15 124 patients from 105 centers (median age, 71 years; 49% men; 39% treated with intravenous thrombolysis only; and 61% with endovascular treatment±intravenous thrombolysis), 849 (5.6%) had COVID-19, of whom 395 (46%) were asymptomatic and 454 (54%) symptomatic. Compared with controls, both patients with AS-COVID and S-COVID had higher symptomatic intracerebral hemorrhage rates (COVID-controls, 5%; AS-COVID, 7.6%; S-COVID, 9.4%; adjusted odds ratio [aOR], 1.43 [95% CI, 1.03-1.99]; aOR, 1.63 [95% CI, 1.14-2.32], respectively). Only in patients with symptomatic infections, we observed a significant increase in mortality at 24 hours (COVID-controls, 1.3%; S-COVID, 4.8%; aOR, 2.97 [95% CI, 1.76-5.03]) and 3 months (COVID-controls, 19.5%; S-COVID, 40%; aOR, 2.64 [95% CI, 2.06-3.37]). Patients with COVID-19 had worse 3-month disability regardless of disease symptoms although disability was affected to a greater extent in symptomatic patients (aOR for worse modified Rankin Scale score shift: AS-COVID, 1.25 [95% CI, 1.03-1.51]; S-COVID, 2.10 [95% CI, 1.75-2.53]). S-COVID had lower successful recanalization (74.9% versus 85.6%; P<0.001), first pass recanalization (20.3% versus 28.3%; P=0.005), and a higher number of passes. CONCLUSIONS: In AIS undergoing revascularization treatments, both AS-COVID and S-COVID influence the risk of intracranial bleeding and worse clinical outcomes. The magnitude of this effect is more pronounced in symptomatic infections, which also present less favorable recanalization outcomes. These findings emphasize the impact of SARS-CoV-2 infection on the prognosis of revascularized AIS independent of symptom status. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04895462.

Departement of Internal Medicine Faculty of Medicine University of Thessaly Larissa Greece

Departement of Neurology Boston Medical Center MA

Department of Neurology Hospital de Egas Moniz Centro Hospitalar Lisboa Ocidental Portugal

Stroke Center Neurology Service Department of Neurological Sciences Lausanne University Hospital University of Lausanne Switzerland

89 PubMed

Zobrazit více v PubMed

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al. . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127 PubMed PMC

Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, et al. . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013 PubMed PMC

Nguyen TN, Qureshi MM, Klein P, Yamagami H, Abdalkader M, Mikulik R, Sathya A, Mansour OY, Czlonkowska A, Lo H, et al. ; SVIN COVID-19 Global COVID Stroke Registry. Global impact of the COVID-19 pandemic on cerebral venous thrombosis and mortality. J Stroke. 2022;24:256–265. doi: 10.5853/jos.2022.00752 PubMed PMC

Sashindranath M, Nandurkar HH. Endothelial dysfunction in the brain: setting the stage for stroke and other cerebrovascular complications of COVID-19. Stroke. 2021;52:1895–1904. doi: 10.1161/strokeaha.120.032711 PubMed PMC

Sagris D, Papanikolaou A, Kvernland A, Korompoki E, Frontera JA, Troxel AB, Gavriatopoulou M, Milionis H, Lip GYH, Michel P, et al. . COVID-19 and ischemic stroke. Eur J Neurol. 2021;28:3826–3836. doi: 10.1111/ene.15008 PubMed PMC

Endres M, Moro MA, Nolte CH, Dames C, Buckwalter MS, Meisel A. Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke. Circ Res. 2022;130:1167–1186. doi: 10.1161/CIRCRESAHA.121.319994 PubMed

Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, Calleja P, Ostos F, Gonzalez-Ortega G, Fuentes B, et al. . Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the Global COVID-19 Stroke Registry. Stroke. 2020;51:e254–e258. doi: 10.1161/STROKEAHA.120.031208 PubMed PMC

Dhamoon MS, Thaler A, Gururangan K, Kohli A, Sisniega D, Wheelwright D, Mensching C, Fifi JT, Fara MG, Jette N, et al. ; Mount Sinai Stroke Investigators. Acute cerebrovascular events with COVID-19 infection. Stroke. 2021;52:48–56. doi: 10.1161/STROKEAHA.120.031668 PubMed

Perry RJ, Smith CJ, Roffe C, Simister R, Narayanamoorthi S, Marigold R, Willmot M, Dixit A, Hassan A, Quinn TJ, et al. ; SETICOS Collaborators. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. J Neurol Neurosurg Psychiatry. 2021;92:242–248. doi: 10.1136/jnnp-2020-324927 PubMed

Srivastava PK, Zhang S, Xian Y, Xu H, Rutan C, Alger HM, Walchok J, Williams J, de Lemos JA, Decker-Palmer MR, et al. . Acute ischemic stroke in patients with COVID-19: an analysis from get with the guidelines-stroke. Stroke. 2021;52:1826–1829. doi: 10.1161/strokeaha.121.034301 PubMed

Fuentes B, Alonso de Lecinana M, Garcia-Madrona S, Diaz-Otero F, Aguirre C, Calleja P, Egido JA, Carneado-Ruiz J, Ruiz-Ares G, Rodriguez-Pardo J, et al. . Stroke acute management and outcomes during the COVID-19 outbreak: a cohort study from the Madrid stroke network. Stroke. 2021;52:552–562. doi: 10.1161/STROKEAHA.120.031769 PubMed

Strambo D, De Marchis GM, Bonati LH, Arnold M, Carrera E, Galletta S, Nedeltchev K, Kahles T, Cereda CW, Bianco G, et al. ; Swiss Stroke Registry Investigators. Ischemic stroke in COVID-19 patients: mechanisms, treatment, and outcomes in a consecutive Swiss Stroke Registry analysis. Eur J Neurol. 2022;29:732–743. doi: 10.1111/ene.15199 PubMed PMC

Marto JP, Strambo D, Ntaios G, Nguyen TN, Herzig R, Czlonkowska A, Demeestere J, Mansour OY, Salerno A, Wegener S, et al. ; Global COVID-19 Stroke Registry. Safety and outcome of revascularization treatment in patients with acute ischemic stroke and COVID-19: the Global COVID-19 Stroke Registry. Neurology. 2023;100:e739–e750. doi: 10.1212/WNL.0000000000201537 PubMed PMC

European Centre for Disease Prevention and Control. Case definition for COVID-19, as of 3 December 2020. Stockholm: ECDC; 2020. https://www.ecdc.europa.eu/en/covid-19/surveillance/surveillance-definitions

WHO COVID-19: Case Definitions. 2022. https://www.who.int/publications/i/item/who-2019-nCoV-surveillanceguidance-2020.7

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349. doi: 10.1016/j.jclinepi.2007.11.008 PubMed

Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. . Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245–1251. doi: 10.1016/s0140-6736(98)08020-9 PubMed

Zaidat OO, Castonguay AC, Linfante I, Gupta R, Martin CO, Holloway WE, Mueller-Kronast N, English JD, Dabus G, Malisch TW, et al. . First pass effect: a new measure for stroke thrombectomy devices. Stroke. 2018;49:660–666. doi: 10.1161/strokeaha.117.020315 PubMed

van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67. doi: 10.18637/jss.v045.i03

Marcos-Contreras OA, Martinez de Lizarrondo S, Bardou I, Orset C, Pruvost M, Anfray A, Frigout Y, Hommet Y, Lebouvier L, Montaner J, et al. . Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. Blood. 2016;128:2423–2434. doi: 10.1182/blood-2016-03-705384 PubMed

Hernández-Fernández F, Valencia HS, Barbella-Aponte RA, Collado-Jiménez R, Ayo-Martín O, Barrena C, Molina-Nuevo JD, García-García J, Lozano-Setién E, Alcahut-Rodriguez C, et al. . Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain. 2020;143:awaa239. doi: 10.1093/brain/awaa239 PubMed PMC

Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142:68–78. doi: 10.1161/CIRCULATIONAHA.120.047549 PubMed

Cunningham RM, Johnson Moore KL, Moore JS. Coagulopathy during COVID-19 infection: a brief review. Clin Exp Med. 2022;23:655–666. doi: 10.1007/s10238-022-00891-4 PubMed PMC

Siegler JE, Abdalkader M, Michel P, Nguyen TN. Therapeutic trends of cerebrovascular disease during the COVID-19 pandemic and future perspectives. J Stroke. 2022;24:179–188. doi: 10.5853/jos.2022.00843 PubMed PMC

Li M, Zhang Y, Lu J, Li L, Gao H, Ma C, Dai E, Wei L. Asymptomatic COVID-19 individuals tend to establish relatively balanced innate and adaptive immune responses. Pathogens. 2021;10:1105. doi: 10.3390/pathogens10091105 PubMed PMC

Varner KB, Cox EJ. COVID-19 as the cause of thrombosis: recognising COVID-19 infection in apparently asymptomatic patients. BMJ Case Rep. 2021;14:e241027. doi: 10.1136/bcr-2020-241027 PubMed PMC

Umemura T, Kondo H, Ohta H, Futatsuya K, Mizobe T, Yamamoto J. D-dimer level elevation can aid in detection of asymptomatic COVID-19 presenting with acute cerebral infarction. eNeurologicalSci. 2021;22:100294. doi: 10.1016/j.ensci.2020.100294 PubMed PMC

Caesario J, Hertanto DM, Hernugrahanto KD, Utomo DN, Budhiparama NC, Santoso D, Hogendoorn PCW. Case report: asymptomatic COVID-19 patient with a subtle hypercoagulable state and fluctuating D-dimer level. F1000Res. 2021;10:1112. doi: 10.12688/f1000research.74009.1 PubMed PMC

Escalard S, Maier B, Redjem H, Delvoye F, Hebert S, Smajda S, Ciccio G, Desilles JP, Mazighi M, Blanc R, et al. . Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke. 2020;51:2540–2543. doi: 10.1161/STROKEAHA.120.030574 PubMed PMC

Genchi A, Semerano A, Schwarz G, Dell’Acqua B, Gullotta GS, Sampaolo M, Boeri E, Quattrini A, Sanvito F, Diamanti S, et al. . Neutrophils predominate the immune signature of cerebral thrombi in COVID-19 stroke patients. Acta Neuropathol Commun. 2022;10:14. doi: 10.1186/s40478-022-01313-y PubMed PMC

Wang A, Mandigo GK, Yim PD, Meyers PM, Lavine SD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J Neurointerv Surg. 2020;12:648–653. doi: 10.1136/neurintsurg-2020-016220 PubMed

Pop R, Hasiu A, Bolognini F, Mihoc D, Quenardelle V, Gheoca R, Schluck E, Courtois S, Delaitre M, Musacchio M, et al. . Stroke thrombectomy in patients with COVID-19: initial experience in 13 cases. AJNR Am J Neuroradiol. 2020;41:2012–2016. doi: 10.3174/ajnr.A6750 PubMed PMC

Nguyen TN, Qureshi MM, Klein P, Yamagami H, Mikulik R, Czlonkowska A, Abdalkader M, Sedova P, Sathya A, Lo HC, et al. ; and the SVIN COVID-19 Global Stroke Registry. Global impact of the COVID-19 pandemic on stroke volumes and cerebrovascular events: a 1-year follow-up. Neurology. 2023;100:e408–e421. doi: 10.1212/WNL.0000000000201426 PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT04895462